Bangkok, August 1st 2025 –  The official launch of Zerpidio (Serplulimab) in Thailand represents an important milestone in strengthening access to innovative cancer therapies in Southeast Asia. This achievement reflects Kalbe’s commitment to advancing treatment options and addressing the significant unmet needs of patients living with lung cancer in the region.

Zerpidio is an immune checkpoint inhibitor, that works by blocking the PD-1 protein on immune cells called T-cells, which allows the immune system to better recognize and attack cancer cells. In Thailand, it is being introduced with two approved indications:

·       Extensive-stage small cell lung cancer (ES-SCLC)

·       Squamous non-small cell lung cancer (sq-NSCLC)

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, and current treatment options are often limited. The availability of Zerpidio provides healthcare professionals in Thailand with a new therapeutic option to support improved patient outcomes.

In Thailand, Zerpidio is marketed by Alliance Pharma, a partner with established expertise in oncology and a strong focus on patient access. The official launch event, held on August 1, 2025, brought together leading healthcare professionals, partners, and stakeholders to mark this significant development in the country’s cancer care landscape.

The potential of Zerpidio is already being demonstrated in real-world practice. Since its launch in Indonesia in 2024, the therapy has been made available to patients with ES-SCLC and sq-NSCLC, with encouraging treatment experiences that align with clinical trial evidence. These outcomes highlight the important role Zerpidio can play in improving quality of life for patients and supporting their families in the fight against lung cancer.

Following Indonesia and Thailand, Zerpidio has received regulatory approvals in Singapore and Malaysia for the treatment of ES-SCLC, with approval in the Philippines expected in the near future. These approvals underscore our dedication to expanding access to innovative immuno-oncology therapies across Southeast Asia.

As we move forward with upcoming launches, Kalbe remains focused on collaborating with healthcare professionals, regulators, and partners to strengthen treatment pathways, support clinical practice, and broaden patient access.

Each approval represents progress toward our mission: to deliver innovative therapies that address urgent healthcare challenges and contribute to improving the quality of life for patients across the region.